Know Cancer

or
forgot password

Transarterial Chemoembolization Versus Best Support for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis


Phase 4
18 Years
75 Years
Not Enrolling
Both
Hepatocellular Carcinoma

Thank you

Trial Information

Transarterial Chemoembolization Versus Best Support for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis


Inclusion Criteria:



- The diagnosis of HCC was based on the diagnostic criteria for HCC used by the
European Association for the Study of the Liver (EASL)

- Tumor size >7 cm with a portal vein invasion, and the tumor was considered to be
unresectable

- No previous HCC directed treatment

- Eastern Co-operative Group performance status 0-1

- Liver function: Child's A

Exclusion Criteria:

- Avascular tumor

- Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or
hepatic encephalopathy

- underlying serve cardiac or renal diseases

- Known or suspected allergy to the investigational agent or any agent given in
association with this trial

- Diffuse-type HCC

- For patients with main portal vein occlusion, no adequate collateral circulation
around the occluded portal vein

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

survival rates

Outcome Time Frame:

6, 12 months

Safety Issue:

Yes

Principal Investigator

jinqing li, MD

Investigator Role:

Study Director

Investigator Affiliation:

cancer canter sun yat-set university

Authority:

China: Ministry of Health

Study ID:

TACE1

NCT ID:

NCT00646100

Start Date:

July 2007

Completion Date:

February 2010

Related Keywords:

  • Hepatocellular Carcinoma
  • hepatocellular carcinoma
  • transcatheter arterial chemoembolization
  • prospective control study
  • best support care
  • survival
  • Carcinoma
  • Thrombosis
  • Carcinoma, Hepatocellular

Name

Location